Genital Warts (Condyloma Acuminatum) Market

• The Genital Warts market size in 7MM was nearly USD 860 million in 2023, which is further expected to increase by 2034 at a significant Compound Annual Growth Rate (CAGR) for the study period (2020–2034).
• In 2023, approximately 866k incident cases of Genital Warts (Condyloma Acuminatum) existed in the 7MM. Factors contributing to the rise in incident cases of genital warts in the 7MM includes improved detection and reporting, decreased immunity, and changes in sexual behavior.
• When the incident cases of genital warts were segmented based on gender in the 7MM, a higher number of cases was observed in the females as compared to males. In 2023, approximately 459k females were found to be affected by genital warts in the 7MM, and these cases are further projected to change during the study period (2020-2034).
• In the 7MM, the United States accounted for the highest number of genital warts incident cases, totaling approximately 547k cases in 2023, and these cases are further expected to increase during the study period (2020-2034).
• In Japan, incidence of genital warts cases is the highest among people with age 18-29 years of age followed by 30 to 39 years of age and 40 and above years of age. In 2023, there were 15,731 cases among 18-29 years age group, 10,988 cases among 30-39 years age-group and 10,842 cases among 40 and above age group.
• Among the currently approved treatments for genital warts, Topical Agents are expected to garner the highest market size by 2034 in the 7MM.
• Growth of the genital warts market is expected to be mainly driven by improved diagnostic approaches, an upsurge in the launch of products, and increasing research in pharmaceutical treatment.

Request for Sample Page @ Genital Warts Market Report

DelveInsight’s report titled “Genital Warts (Condyloma Acuminatum) Market Insights, Epidemiology, and Market Forecast – 2034” comprehensively analyzes genital warts. The report provides a comprehensive analysis of historical and projected epidemiological data, covering Incident cases of genital warts, Gender- specific Incident cases of genital warts, Age- specific Incident cases of genital warts, and Incident cases of genital warts by Anatomical Location.

The Genital Warts market report provides a comprehensive insight into different facets concerning the patient population, encompassing diagnosis, prescribing trends, physician viewpoints, market accessibility, therapy, and forthcoming market advancements across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan spanning from 2020 to 2034.

The report examines current treatment methodologies and algorithms for genital warts, assessing the overall market potential, identifying business prospects, and addressing the unmet medical requirements.

Genital Warts Diagnosis Treatment Market

Clinical diagnosis of GW is based on the appearance of warts, whereas histopathological diagnosis is not routinely indicated. Nucleic Acid Amplification Test for HPV DNA is also recommended. Accurate diagnosis is an essential first step in the treatment of Genital Warts. Also, Pap test, HPV tests and newer technologies like Dermatoscopy are being used.

The current options available for the treatment of Genital Warts are primarily centered upon removal of the warty growth rather than elimination of the underlying viral infection. Common treatments include topical therapeutic agents; physical removal of warts with cryotherapy, electrocautery or lasers; or photodynamic therapy along with vaccines. The criteria for warts treatment, developed by the American Academy of Dermatology include: the patient’s desire for therapy, symptoms of pain, bleeding, itching or burning; (3) disabling or disfiguring lesions; (4) large numbers or large sizes of lesions; (5) the patient’s desire to prevent the spread of warts to unblemished skin of self or others; and (6) an immunocompromised condition.

There are currently three approved vaccines for the prevention of HPV infection, Gardasil (recombinant HPV quadrivalent vaccine, Types 6, 11, 16, and 18; Merck), Gardasil (recombinant HPV nonavalent vaccine; Merck) and Cervix (recombinant HPV bivalent vaccine, Types 16 and 18; GlaxoSmithKline). The vaccines are prepared from viral proteins but do not contain viral DNA. Therefore, neither vaccine can cause HPV infection. Both vaccines were designed for the prevention of HPV infection and did not treat existing HPV infection or disease.  The therapeutic pipeline is active with many novel topical formulations like SB206, VP-102 and others in development.

Genital Warts Overview

Human papillomavirus (HPV) is a small, nonenveloped, double-stranded DNA virus. Most of the HPV-related diseases and research are focused on HPV types within the alpha group. Individual types are further classified as high-risk (e.g., HPV16 and 18) and low-risk HPV (e.g., HPV6 and 11) based on oncogenic potential. E6 and E7 are the main oncoproteins, with E6 binding to p53.

Genital warts (also known as anogenital warts, condylomata acuminata, condylomas) are benign proliferative lesions caused by human papillomavirus (HPV) types 6 and 11, which are found in >95% of lesions. Genital warts (Genital Warts) are transmitted by having sexual contact with someone who already has them and may be found on the outside of genitals. Some types, which cause cancer, result in the growth of lesions on a woman's cervix. It is possible to get genital warts, HPV infection, even if they are not visible. Besides, they look like flesh-colored bumps that have a cauliflower-like appearance, and are usually flat, papular, or pedunculated growths on the genital mucosa, occurring in clusters.

Genital Warts can appear on the penis, vulva, vagina, cervix, groin, or thigh within weeks or months after sexual contact with an infected person. Potentially cancer-causing HPV strains are spread by sexual intercourse, anal sex, and oral sex.

Genital Warts Epidemiology

The epidemiology section on genital warts offers an analysis of past and present patient populations, along with projected trends across seven major countries (7MM). Drawing from multiple studies and expert opinions, it aims to elucidate the underlying factors driving current and anticipated trends. Additionally, this segment of the report presents data on the diagnosed patient population, highlighting trends and underlying assumptions.

Key Findings

• The total incident cases of genital warts in the 7MM was found to be 860k in the year 2023. These cases are expected to change significantly by 2034.
• The United States accounted for around 547k incident cases of genital warts in 2023.
• When the incident population of genital warts was segmented based on anatomical location, in the United States, in 2023, there were nearly 257k cases for Vulva, which are the highest number of cases followed by cases with unspecified location (164k) and for Cervix with (84k) cases. The least number of cases were observed in Anal/genital or Anal/recta.
• In EU4 and the UK, Germany had the highest incident cases of genital warts with approximately 75k cases, followed by the France and UK with around 55k cases.  Projections indicate a substantial change in these cases by the year 2034.
• In 2023, Japan had around 37k incident cases of genital warts ranking the lowest among 7MM. These cases are expected to further decrease by 2034.
• In Japan, males diagnosed with genital warts are higher in number than females. In 2023, the incident cases of genital warts among females were reported to be around 15k cases while that among male population, these were 22 thousand cases. These numbers are expected to decrease during the study period (2020-2034).

Uncover the latest projections and insights on Genital Warts Epidemiology Forecast for 2032. Stay informed, explore now!

Genital Warts Drug Chapters

The drug chapter segment of the genital warts report encloses the detailed analysis of genital warts marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the genital warts clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

Genital Warts Marketed Therapies

The current options available for the treatment of genital warts are primarily centered upon removal of the warty growth rather than elimination of the underlying viral infection. Common treatments include i) topical therapeutic agents; ii) physical removal of warts with cryotherapy, electrocautery or lasers; or iii) photodynamic therapy. Also, little evidence suggests that existing treatments are effective in the long-term eradication of genital warts or that they play any significant role in hindering potential malignant wart evolution. Wide range of therapies is presently in use, which is highly variable and can differ dramatically concerning cost, side-effect profiles, dosing schedules, duration of treatment, and overall effectiveness. As of now, no definitive therapy has emerged as the ideal standard of care in the treatment of genital warts, and therapy selection generally occurs in a patient-specific manner.

Imiquimod: Medicis Pharmaceuticals

Imiquimod (Zyclara/Aldara) is an immune response modifier. It is a prescription medicine used to treat actinic keratosis (a condition caused by extensive sun exposure) on the face and scalp of adults who are over 18 years of age. It is also used to treat genital warts that appear on the outside of the body in adults and children who are at least 12 years old. This medicine is not a cure for genital warts.

Veregen (Polyphenon E): Aresus Pharma

Veregen, first drug in its class for the local treatment of genital warts, is based on a defined extract of green tea leaves produced in a complex and specifically developed process. Veregen was the first and is one of the few innovative herbal medicines which were approved by the US Food and Drug Administration (FDA).

Genital Warts Emerging Therapies

The potential drugs that are expected to launch in the forecasted period include VP-102, and others.

VP-102: Verrica Pharmaceuticals

VP-102 is a proprietary drug-device combination of 0.7% w/v cantharidin delivered via a single-use precision applicator. The active ingredient, cantharidin, is a naturally occurring vesicant that causes the degradation of desmosomal plaques. It is topical, applied directly to the lesions, and designed to be convenient for both patients and practitioners. Verrica is also advancing its lead product, VP-102, a proprietary topical therapy, in many common skin indications, including molluscum contagiosum and verruca vulgaris. Verrica has announced positive top-line results from its CARE-1 Phase II study and intends to conduct additional studies of VP-102 for the treatment of external genital warts.

SB207: Novan

In October 2019, Novan anticipates that SB207 is a product candidate well-suited for an external genital warts program. The drug substance in SB207 has previously been tested in Phase II clinical studies of Novan’s existing product candidate (SB206) for external genital warts and molluscum contagiosum. Data from these trials demonstrated that SB206 was both efficacious and well-tolerated. The SB207 product incorporates the existing drug substance, berdazimer sodium, with a new formulation specifically engineered and tailored to be effective within a number of viral indications.

Note: Detailed emerging therapies assessment and list of products to be continued in the report....

Genital Warts Market Outlook

Genital warts (GW) are caused by infection with human papillomavirus (HPV) and primary prevention of genital warts is possible through HPV vaccination. HPV infection is only treatable when it's causing warts. This treatment is mainly targeted towards warts and it doesn't affect the HPV infection and no direct treatment for the virus is available. In some people the immune system gets rid of the HPV infection quickly and thus gains immunity. In others the virus may remain for longer time.

The market revenue of Genital warts doesn’t include the sales of prophylactic vaccines, owing to the fact that the vaccination is done as a preventive measure of overall HPV infections, and not specifically for genital warts.

Currently, the primary therapeutic approaches for treating genital warts focus on removing the warts themselves. However, there is limited evidence supporting the long-term effectiveness of existing treatments in completely eradicating genital warts or significantly reducing the rate of recurrence.

Note: Detailed market outlook to be continued in the report....

Genital Warts Market Segmentation

DelveInsight’s ‘Genital Warts (Condyloma Acuminatum) – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future genital warts market, segmented within countries and by therapies. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Genital Warts Market Size by Countries

The total genital warts market size is analyzed for individual countries (the United States Market, EU4 (Germany, France, Italy, and Spain) and the UK market, and Japan). The United States accounted for a larger portion of the 7MM market for Genital Warts in 2023 due to the higher cases of the condition and high treatment cost. This dominance is predicted to continue with the potential early entry of new products.

Country-wise Market Size Distribution of Genital Warts

Genital Warts Market Size by Therapies

The aim of treatment in genital warts is the removal of warts and amelioration of symptoms, if present. The appearance of warts result in considerable psychosocial and its treatment results in the resolution of the warts. If left untreated, anogenital warts can resolve spontaneously, remain unchanged, or increase in size or number. Warts might spontaneously resolve in <1 year, an acceptable alternative for certain patients is to forego treatment and wait for spontaneous resolution. Available therapies for anogenital warts might reduce, but probably do not eradicate, HPV infectivity.

Treatment of anogenital warts should be guided by wart size, number, and anatomic site; patient preference; cost of treatment; convenience; adverse effects; and provider experience. No definitive evidence indicates that any one recommended treatment is superior to another, and no single treatment is ideal for all patients or all warts. Since, all available treatments have shortcomings, clinicians sometimes use combination therapy (e.g., provider-administered cryotherapy with patient-applied topical therapy between visits to the provider). However, limited data exist regarding the efficacy or risk for complications associated with combination therapy. Treatment regimens are classified as either patient-applied or provider-administered modalities. Patient-applied modalities are preferred by certain persons because they can be administered in the privacy of their home.

It is believed that the Genital Warts treatment market could change by 2034, in the US with the launch of novel therapies with better and broader efficacy, treatment duration, better dosages, and enhanced convenience.

Key Findings

• The Genital Warts market size in 7MM was nearly USD 860 million in 2023, which is further expected to increase by 2034 at a significant Compound Annual Growth Rate (CAGR) for the study period (2020–2034).
• The United States accounts for the largest market size for genital warts accounting for around 75% of the total 7MM market size.
• Upcoming therapies such as VP-102, SB207, and others have the potential to create a significant positive shift in the genital warts market size.
• Among the European countries, Germany had the highest market size with approximately USD 51 million in 2023.
• The expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in the incident cases of genital warts.

Note: Detailed market segment assessment will be provided in the final report....

Genital Warts Drugs Uptake

This section focuses on the sales uptake of potential genital warts drugs that have recently launched or are anticipated to be launched in the genital warts market between 2020 and 2034. It estimates the market penetration of the genital warts drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the drug’s probability of success (PoS) in the genital warts market.

For example, for VP-102, we expect the drug uptake to be slow-medium with a probability-adjusted peak share of around 18%, and years to the peak is expected to be 7 years from the year of launch in the US.

Explore the forefront of Genital Warts research. Dive into our comprehensive Genital Warts Pipeline Insight for 2024. Stay informed, act decisively.

Genital Warts Market Access and Reimbursement

DelveInsight’s ‘Genital Warts – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of genital warts.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current genital warts market trends and fill gaps in secondary findings, we interview KOLs and SMEs working in the genital warts domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or genital warts market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the genital warts unmet needs.

Genital Warts: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Department of Epidemiology and Population Health, Albert Einstein College of Medicine, USA, Department of Dermatology, Yale School of Medicine, USA, University of Texas Medical Branch, Galveston, USA, Klinikum der Universität München, Deutschland, Germany, Klinikum der Universität München, Deutschland, Germany and others.

“Genital warts affected male erections more than other areas of sexual function. SD (Sexual Dysfunction) in men in genital warts has a significant impact on their lives and is associated with impaired sexual function and quality of life (SQOL). Therefore, it is advisable to pay more attention to SD screening in parallel with the SQOL assessment of men with genital warts.”

“In Germany, treatment and recurrence rates for genital warts remain difficult due to the still inadequate vaccination coverage of prophylactic HPV vaccination. This underscores the importance of the recently adopted interdisciplinary German guidelines for anal genital HPV lesions.”

Note: Detailed assessment of KOL Views will be provided in the full report of Genital Warts.....

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the genital warts market using various Competitive Intelligence tools, including SWOT analysis, conjoint analysis, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

The emerging genital warts therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the genital warts market.

Note: Detailed assessment of SWOT analysis and conjoint analysis will be provided in the full report on Genital Warts....

Genital Warts Pipeline Development Activities

The report provides insights into genital warts clinical trials within Phase II and III stages. It also analyzes genital warts Companies involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging genital warts therapies.

Scope of the Genital Warts Market Report

• The report covers a segment of key events, an executive summary, descriptive overview of genital warts, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression along with treatment guidelines
• Additionally, an all-inclusive account of both the current and emerging therapies along with the elaborative profiles of late-stage and prominent therapies will have an impact on the current treatment landscape
• A detailed review of the genital warts market; historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preference that help in shaping and driving the 7MM genital warts market.

Genital Warts Report Insights

• Genital Warts Patient Population
• Genital Warts Therapeutic Approaches
• Genital Warts Pipeline Analysis
• Genital Warts Market Size and Trends
• Existing and future Market Opportunity

Genital Warts Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Genital Warts Epidemiology Segmentation
• Key Cross Competition
• Attribute analysis
• Genital Warts Drugs Uptake
• Key Genital Warts Market Forecast Assumptions

Genital Warts Report Assessment

• Current Genital Warts Treatment Practices
• Genital Warts Unmet Needs
• Genital Warts Pipeline Product Profiles
• Genital Warts Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Genital Warts Market Drivers
• Genital Warts Market Barriers

Key Questions Answered In The Genital Warts Market Report:

Genital Warts Market Insights:

• What was the genital warts total market size, the market size by therapies, and market share (%) distribution in 2020, and how it would all look in 2034? What are the contributing factors for this growth?
• What are the unmet needs are associated with the current treatment market of genital warts?
• How is VP-102 going to contribute to the market of genital warts after approval?
• Which drug is going to be the largest contributor in 2034?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Genital Warts Epidemiology Insights:

• What are the disease risk, burden, and unmet needs of genital warts? What will be the growth opportunities across the 7MM concerning the patient population of genital warts?
• What is the historical and forecasted genital warts patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• What factors are affecting the diagnosis and treatment of the indication?

Current Genital Warts Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of genital warts? What are the current treatment guidelines for the treatment of genital warts in the US and Europe?
• How many genital warts companies are developing therapies for the treatment of genital warts?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of genital warts?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the key designations that have been granted for the emerging therapies for genital warts?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted market of genital warts?

Reasons to buy Genital Warts Market Report

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the genital warts Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders’ around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in future.
• Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions

1.            What are the treatment goals for Genital Warts?

The treatment goals for genital warts are to relieve symptoms, remove visible warts, prevent complications and transmission, minimize recurrence, and address the psychological impact associated with the condition, ultimately aiming to improve overall well-being and quality of life for affected individuals.

2.            What are the challenges in managing Genital Warts?

Managing genital warts poses several challenges, including the potential for recurrence despite treatment, the asymptomatic nature of the infection in some cases, the risk of transmission to sexual partners even when warts are not visible, the psychological impact on individuals, the lack of a cure for the underlying human papillomavirus (HPV) infection, and barriers to accessing healthcare and prevention measures such as vaccination. Additionally, stigma surrounding sexually transmitted infections may hinder open communication and effective management strategies.

3.            What are the key factors driving the growth of the Genital Warts market?

The Genital Warts market is propelled by factors like increasing cases, medical advancements, rising awareness, and the introduction of novel therapies by key pharmaceutical players. These elements fuel demand for innovative treatments, addressing unmet medical needs and driving market expansion.

4.            How will the Genital Warts Market and Epidemiology Forecast Report benefit the clients?

The report will provide comprehensive insights into the current Genital Warts market landscape, emerging therapies, competitive dynamics, regulatory requirements, and market access considerations, enabling informed decision-making, strategic planning, and optimization of business strategies to capitalize on market opportunities and drive growth.